Preliminary pharmacokinetic and MRD results from AML patients treated with 7- and 14-day dosing schedule of emavusertib added to combination therapy with azacitidine and venetoclax

Venclexta (venetoclax) - Roche, AbbVie

azacitidine - Generic mfg.

emavusertib (CA-4948) - Curis, Dr. Reddy’s

https://meetings-api.hematology.org/api/abstract/vmpreview/299854

Cristina Papayannidis1; Ulf Schnetzke2; Maximilian Fleischmann2; Adolfo De La Fuente Burguera3; Klaus Metzeler4; Maureen Lane5; Li Zhou5; Ahmed Hamdy5; Claudio Cerchione6

Nov 4, 2025